Data demonstrating the efficacy and tolerability of DAC/SORA in patients with R/R AML with FLT3-ITD [131] have led to NCCN recommendations for the use of AZA/SORA or DAC/SORA as low-intensity therapy in elderly patients with FLT3-ITD AML or in R/R AML with FLT3-ITD [45], though it does not carry FDA approval for these indications. This evidence concerns the gene FLT3 and acute myeloid leukemia.